ESC 365 - Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review

ESC Professional Premium Access

Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review

Session: Treatment of pulmonary arterial hypertension: the old and the new

Topic: Pulmonary Hypertension

Speaker: Doctor M. Sketch (Research Triangle Park, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Margaret Sketch

United Therapeutics Corporation, Research Triangle Park (United States of America)

0 follower

4 more presentations in this session

Efficacy and dose-response relationship of oral treprostinil in PAH patients on monotherapy or dual background therapy

Speaker: Doctor J. Barbera (Barcelona, ES)

UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)

Speaker: Professor V. McLaughlin (Ann Arbor, US)

Macitentan for pulmonary arterial hypertension related to repaired congenital heart disease: Real-world UK experience

Speaker: Doctor A. Constantine (Birmingham, GB)

Human umbilical cord mesenchymal stem cells attenuate experimental pulmonary arterial hypertension

Speaker: Professor H. Dai (Kunming, CN)

Access the full session

Treatment of pulmonary arterial hypertension: the old and the new

Speakers: Doctor M. Sketch, Doctor J. Barbera, Professor V. McLaughlin, Doctor A. Constantine, Professor H. Dai

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources